{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:46Z","timestamp":1788401626342,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","award":["4199990514025"],"award-info":[{"award-number":["4199990514025"]}],"id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003646","name":"National Health Insurance Service","doi-asserted-by":"publisher","award":["KDCA-NHIS-2024-11-070"],"award-info":[{"award-number":["KDCA-NHIS-2024-11-070"]}],"id":[{"id":"10.13039\/501100003646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["2021M3E5E3081366"],"award-info":[{"award-number":["2021M3E5E3081366"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jinf.2026.106753","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:36:36Z","timestamp":1777466196000},"page":"106753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation"],"prefix":"10.1016","volume":"92","author":[{"given":"Hyun-Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-0160","authenticated-orcid":false,"given":"Suyoung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Duk","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-1494","authenticated-orcid":false,"given":"Sung-il","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106753_bib1","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccination guidance forpeople who are immunocompromised. Covid; 2025. \u3008\u3008https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\u3009\u3009 [Accessed November 12,2025]."},{"key":"10.1016\/j.jinf.2026.106753_bib2","unstructured":"Korea Disease Control and Prevention Agency. COVID-19 national immunizationprogram (temporary implementation). \u3008\u3008https:\/\/nip.kdca.go.kr\/irhp\/covd\/goCov19Vcnt.do?menuLv=4&menuCd=47\u3009\u3009 [Accessed November 12, 2025]."},{"key":"10.1016\/j.jinf.2026.106753_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","article-title":"2021 update of the AGIHO guideline onevidence-based management of COVID-19 in patients with cancer regardingdiagnostics, viral shedding, vaccination and therapy","volume":"147","author":"Giesen","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.jinf.2026.106753_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines inpatients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib5","first-page":"1431","article-title":"Impact of COVID-19 in cancer patientson severity of disease and fatal outcomes","volume":"14","author":"Salunke","year":"2020","journal-title":"a systematic review and meta-analysis,Diabetes Metab Syndr Clin Res Rev"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation ofCOVID-19 mortality and adverse outcomes in US patients with or without cancer","volume":"8","author":"Chavez-MacGregor","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jinf.2026.106753_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf074","article-title":"COVID-19 burden of illness in people whoare immunocompromised due to cancer: an expert opinion review","volume":"30","author":"Aurer","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jinf.2026.106753_bib8","unstructured":"National Cancer Institute. COVID-19 vaccines and people with cancer - NCI; 2021.\u3008\u3008https:\/\/www.cancer.gov\/about-cancer\/coronavirus\/covid-19-vaccines-people-with-cancer\u3009\u3009 [Accessed November 12, 2025]."},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1186\/s12879-025-11172-2","article-title":"Evaluating the impact of COVID-19 on cancer care:a comprehensive analysis of treatment modifications, risk factors, and patientoutcomes","volume":"25","author":"Jing","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s43018-024-00880-4","article-title":"The global impact of the COVID-19pandemic on delays and disruptions in cancer care services: a systematic review andmeta-analysis","volume":"6","author":"Shah","year":"2025","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.jinf.2026.106753_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ccell.2022.06.012","article-title":"Increased antibody titers andreduced seronegativity following fourth mRNA COVID-19 vaccination in patientswith cancer","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.024","article-title":"Prior COVID-19 protectsagainst reinfection, even in the absence of detectable antibodies","volume":"83","author":"Breathnach","year":"2021","journal-title":"J Infect"},{"issue":"12","key":"10.1016\/j.jinf.2026.106753_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.07.030","article-title":"Rate andseverity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19patients","volume":"27","author":"Slezak","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib14","first-page":"81","article-title":"Reinfection of SARS-CoV-2 variants inimmunocompromised patients with prolonged or relapsed viral shedding","volume":"57","author":"Kim","year":"2025","journal-title":"InfectChemother"},{"issue":"45","key":"10.1016\/j.jinf.2026.106753_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.15585\/mmwr.mm7145a2","article-title":"Interim recommendations fromthe advisory committee on immunization practices for the use of bivalent boosterdoses of COVID-19 vaccines - United States, October 2022","volume":"71","author":"Rosenblum","year":"2022","journal-title":"MMWR Morb Mortal WklyRep"},{"key":"10.1016\/j.jinf.2026.106753_bib16","unstructured":"World Health Organization. Interim statement on decision-making considerationsfor the use of variant updated COVID-19 vaccines. \u3008\u3008https:\/\/www.who.int\/news\/item\/17\u201306-2022-interim-statement-on-decision-making-considerations-for-the-use-of-variant-updated-covid-19-vaccines\u3009\u3009 [Accessed April 2, 2026]."},{"issue":"6","key":"10.1016\/j.jinf.2026.106753_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to Omicron BA.4\u2013BA.5bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jinf.2026.106753_bib18","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original SARS-CoV-2 monovalent andOmicron BA.4\/BA.5 bivalent COVID-19 mRNA vaccines: phase 2\/3 trial interimresults","volume":"29","author":"Chalkias","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jinf.2026.106753_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccinebooster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2026.106753_bib20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2025.2020","article-title":"COVID-19 vaccine booster uptake andeffectiveness among US adults with cancer","volume":"11","author":"Skarbinski","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jinf.2026.106753_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127796","article-title":"Durability ofeffectiveness of a booster dose of COVID-19 bivalent (ancestral\/BA.4-5) vaccineagainst all-cause mortality in older adults in Japan, October 2022 to September2023","volume":"65","author":"Ogata","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib22","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1038\/s41467-024-49285-y","article-title":"Effectiveness of COVID-19vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain","volume":"15","author":"Lazar Neto","year":"2024","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.jinf.2026.106753_bib23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jinf.2026.106753_bib24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa2119497","article-title":"Effectiveness of the BNT162b2vaccine after recovery from Covid-19","volume":"386","author":"Hammerman","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jinf.2026.106753_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004037","article-title":"Vaccine effectivenessagainst SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicrondominance: a Danish nationwide study","volume":"19","author":"Nielsen","year":"2022","journal-title":"PLOS Med"},{"issue":"7","key":"10.1016\/j.jinf.2026.106753_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.23917","article-title":"Effectiveness associated withvaccination after COVID-19 recovery in preventing reinfection","volume":"5","author":"Lewis","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jinf.2026.106753_bib27","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268825000172","article-title":"Characteristics and riskfactors associated with COVID-19 reinfection in Hong Kong: a retrospective cohortstudy","volume":"153","author":"Lin","year":"2025","journal-title":"Epidemiol Infect"},{"issue":"9","key":"10.1016\/j.jinf.2026.106753_bib28","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2023.2271","article-title":"COVID-19 severity and waning immunityafter up to 4 mRNA vaccine doses in 73 608 patients with cancer and 621 475matched controls in Singapore: a nationwide cohort study","volume":"9","author":"Tan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.5771","article-title":"Association of COVID-19 vaccinationwith SARS-CoV-2 infection in patients with cancer","volume":"8","author":"Wu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jinf.2026.106753_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: third dose booster vaccineeffectiveness against breakthrough coronavirus infection, hospitalisations and deathin patients with cancer: a population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jinf.2026.106753_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying atarget trial prevents immortal time bias and other self-inflicted injuries inobservational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"10.1016\/j.jinf.2026.106753_bib32","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework forcausal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib33","first-page":"90","article-title":"Implementation plan for the coronavirus disease2019 vaccination for the 2024\u20132025 season: recommendations of the 6th expertcommittee on immunization practices","volume":"18","author":"Hwang","year":"2025","journal-title":"Public Health Wkly Rep"},{"key":"10.1016\/j.jinf.2026.106753_bib34","unstructured":"Centers for Disease Control and Prevention. 2025\u20132026 COVID-19 vaccinationguidance. \u3008\u3008https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html\u3009\u3009 [Accessed November 12, 2025]."},{"key":"10.1016\/j.jinf.2026.106753_bib35","unstructured":"Ministry of Health and Welfare. National Health Insurance: population coverage,contribution rate & benefit payment < health statistics. \u3008\u3008https:\/\/www.mohw.go.kr\/menu.es?mid=a20310000000\u3009\u3009 [Accessed November 12, 2025]."},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","article-title":"Background and data configuration processof a nationwide population-based study using the Korean national health insurancesystem","volume":"38","author":"Song","year":"2014","journal-title":"Diabetes Metab J"},{"issue":"48","key":"10.1016\/j.jinf.2026.106753_bib37","first-page":"2147","article-title":"Introduction to the researchresults of coronavirus disease 2019 big data (K-COV-N) and the correspondingutilization plan","volume":"17","author":"Lee","year":"2024","journal-title":"Public Health Wkly Rep"},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jiph.2024.03.015","article-title":"Effectiveness of COVID-19 vaccines againstsevere outcomes in cancer patients: real-world evidence from self-controlled riskinterval and retrospective cohort studies","volume":"17","author":"Lee","year":"2024","journal-title":"J Infect Public Health"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.15430\/JCP.2023.28.2.53","article-title":"Economic burden of cancer for the first fiveyears after cancer diagnosis in patients with human immunodeficiency virus inKorea","volume":"28","author":"Jang","year":"2023","journal-title":"J Cancer Prev"},{"issue":"46","key":"10.1016\/j.jinf.2026.106753_bib40","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e396","article-title":"Comparative effectiveness of covid-19bivalent versus monovalent mRNA vaccines in the early stage of bivalent vaccinationin Korea: October 2022 to January 2023","volume":"38","author":"Kim","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"8","key":"10.1016\/j.jinf.2026.106753_bib41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when arandomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13054-025-05723-x","article-title":"Opportunities, challenges and futureperspectives for target trial emulation in critical care clinical research","volume":"29","author":"Reep","year":"2025","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.jinf.2026.106753_bib43","article-title":"Target trial emulation: bridgingobservational studies and randomized trials for health decision-making","volume":"15","author":"Riggi","year":"2026","journal-title":"J Comp EffRes"},{"issue":"12","key":"10.1016\/j.jinf.2026.106753_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting ofobservational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2026.106753_bib45","unstructured":"Pfizer-BioNTech, Pfizer-BioNTech COVID-19 vaccine (BNT162, PF-07302048)vaccines and related biological products advisory committee briefing document,2020, U.S. Food and Drug Administration; Silver Spring (MD)."},{"issue":"3","key":"10.1016\/j.jinf.2026.106753_bib46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmi.2020.11.028","article-title":"Definitions for coronavirus disease 2019reinfection, relapse and PCR re-positivity","volume":"27","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2026.106753_bib47","unstructured":"Centers for Disease Control and Prevention (CDC). About reinfection. COVID-19;2025. \u3008\u3008https:\/\/www.cdc.gov\/covid\/about\/reinfection.html\u3009\u3009 [Accessed November12, 2025]."},{"issue":"24","key":"10.1016\/j.jinf.2026.106753_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response toBNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jinf.2026.106753_bib49","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3201\/eid2810.221045","article-title":"Rapid increase in suspected SARS-CoV-2reinfections, Clark County, Nevada, USA, december 2021","volume":"28","author":"Ruff","year":"2022","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib50","first-page":"S53","article-title":"Using SARS-CoV-2 sequencing data toidentify reinfection cases in the global emerging infections surveillance program,United States","volume":"30","author":"Muehleman","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106753_bib51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trialframework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/EDE.0000000000001808","article-title":"Astructural description of biases that generate immortal time","volume":"36","author":"Hern\u00e1n","year":"2025","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.jinf.2026.106753_bib53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: foundations andmethodological implementation","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probabilityweights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Prog Biomed"},{"issue":"454","key":"10.1016\/j.jinf.2026.106753_bib55","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1198\/016214501753168154","article-title":"Marginal structural models toestimate the joint causal effect of nonrandomized treatments","volume":"96","author":"Hern\u00e1n","year":"2001","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models toestimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.jinf.2026.106753_bib57","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-basedtest-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jinf.2026.106753_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: third dose booster vaccineeffectiveness against breakthrough coronavirus infection, hospitalisations and deathin patients with cancer: a population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PPO.0000000000000587","article-title":"Insights for oncology trials garnered from the rapid development of anmRNA COVID-19 vaccine","volume":"28","author":"Hyer","year":"2022","journal-title":"Cancer J"},{"issue":"10","key":"10.1016\/j.jinf.2026.106753_bib60","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.vaccine.2021.12.046","article-title":"Efficacy and safety of the BNT162b2mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysisof a global phase 3 randomized clinical trial","volume":"40","author":"Thomas","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jinf.2026.106753_bib61","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/vaccines9091048","article-title":"COVID-19 vaccines in cancer patients.Seropositivity and safety. Systematic review and meta-analysis","volume":"9","author":"Cavanna","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2026.106753_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity andrisk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infectionafter coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: asystematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006246","article-title":"COVID-19vaccination in patients with cancer receiving immune checkpoint inhibitors: asystematic review and meta-analysis","volume":"11","author":"Ruiz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jinf.2026.106753_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221106266","article-title":"COVID-19 vaccination in cancer patients: a review article","volume":"29","author":"Mekkawi","year":"2022","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinicalefficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jinf.2026.106753_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(22)00252-2","article-title":"COVID-19 vaccine effectiveness in patients withcancer: remaining vulnerabilities and uncertainties","volume":"23","author":"Kuderer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2022.11.005","article-title":"Age-associatedremodeling of T cell immunity and metabolism","volume":"35","author":"Han","year":"2023","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.jinf.2026.106753_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2567.2004.02006.x","article-title":"Age-related loss of na\u00efve T cells and dysregulation of T-cell\/B-cellinteractions in human lymph nodes","volume":"114","author":"Lazuardi","year":"2005","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib69","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jimmun\/vkae039","article-title":"The cellular factors thatimpair the germinal center in advanced age","volume":"214","author":"Foster","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2026.106753_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105319","article-title":"M. d e S. Aubin, H. Mayfield, A.C. Restrepo, S. Garnier, et al., Convergence of SARS-CoV-2 spikeantibody levels to a population immune setpoint","volume":"108","author":"Nilles","year":"2024","journal-title":"eBioMedicine"},{"issue":"3","key":"10.1016\/j.jinf.2026.106753_bib71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followedby a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jinf.2026.106753_bib72","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.it.2021.09.001","article-title":"Immune imprinting and SARS-CoV-2vaccine design","volume":"42","author":"Wheatley","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jinf.2026.106753_bib73","article-title":"The impact of age difference on the efficacyand safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"FrontImmunol"},{"issue":"14","key":"10.1016\/j.jinf.2026.106753_bib74","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2022.17876","article-title":"Association of primary and booster vaccination andprior infection with SARS-CoV-2 infection and severe COVID-19 outcomes","volume":"328","author":"Lin","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jinf.2026.106753_bib75","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1093\/infdis\/jiaf523","article-title":"COVID-19 vaccine effectiveness in patients with hematologic malignancies: a nationwide cohort study","volume":"233","author":"Hofsink","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106753_bib76","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2021-150439","article-title":"Profound B-Cell lymphopenia isa major factor predicting poor humoral response after BNT162b2 mRNA Sars-Cov-2vaccines in ransplantation","volume":"138","author":"Jullien","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jinf.2026.106753_bib77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity,and safety of COVID-19 vaccines for individuals with hematological malignancies: asystematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jinf.2026.106753_bib78","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.chom.2022.01.003","article-title":"Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections","volume":"30","author":"Terreri","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"14","key":"10.1016\/j.jinf.2026.106753_bib79","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer:aSCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jinf.2026.106753_bib80","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41375-025-02649-9","article-title":"Post-pandemic recommendations forthe management of COVID-19 in patients with haematological malignancies orundergoing cellular therapy, from the European Conference on Infections inLeukaemia (ECIL-10)","volume":"39","author":"Cesaro","year":"2025","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jinf.2026.106753_bib81","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/v15102066","article-title":"Remdesivir or Nirmatrelvir\/Ritonavirtherapy for Omicron SARS-CoV-2 infection in hematological patients and celltherapy recipients","volume":"15","author":"Pi\u00f1ana","year":"2023","journal-title":"Viruses"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:44:26Z","timestamp":1783129466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0163445326000782"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106753","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106753"}}